MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer.

IF 2.8 4区 医学 Q3 ONCOLOGY Technology in Cancer Research & Treatment Pub Date : 2025-01-01 DOI:10.1177/15330338241297231
Andrea Gaetano Allegra, Luca Nicosia, Michele Rigo, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Niccolò Giaj-Levra, Davide Gurrera, Stefania Naccarato, Edoardo Pastorello, Francesco Ricchetti, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi
{"title":"MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer.","authors":"Andrea Gaetano Allegra, Luca Nicosia, Michele Rigo, Nicola Bianchi, Riccardo Filippo Borgese, Antonio De Simone, Niccolò Giaj-Levra, Davide Gurrera, Stefania Naccarato, Edoardo Pastorello, Francesco Ricchetti, Gianluisa Sicignano, Ruggero Ruggieri, Filippo Alongi","doi":"10.1177/15330338241297231","DOIUrl":null,"url":null,"abstract":"<p><p>MR-guided radiotherapy (MRgRT) is novel treatment modality in Radiation Oncology that could allow a higher precision and tolerability of Radiation Treatments. This modality is possible due to dedicated systems consisting of a MR scanner mounted on a conventional linac and software that permit daily online treatment plan adaptation. Prostate cancer (PC) is one of the most common malignancies in RO clinical practice and currently under investigation with this new technology. The focus of this review is to describe the current state of the art and clinical results of MRgRT in the treatment of PC. The available technology are briefly described, as well as the published literature and possible future applications.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241297231"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770696/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology in Cancer Research & Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15330338241297231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

MR-guided radiotherapy (MRgRT) is novel treatment modality in Radiation Oncology that could allow a higher precision and tolerability of Radiation Treatments. This modality is possible due to dedicated systems consisting of a MR scanner mounted on a conventional linac and software that permit daily online treatment plan adaptation. Prostate cancer (PC) is one of the most common malignancies in RO clinical practice and currently under investigation with this new technology. The focus of this review is to describe the current state of the art and clinical results of MRgRT in the treatment of PC. The available technology are briefly described, as well as the published literature and possible future applications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
磁共振引导下的适应性放疗治疗局限性前列腺癌。
磁共振引导放射治疗(MRgRT)是放射肿瘤学中一种新的治疗方式,可以提高放射治疗的精度和耐受性。这种模式是可能的,因为专用系统包括安装在传统直线加速器上的MR扫描仪和允许每日在线治疗计划调整的软件。前列腺癌(PC)是RO临床实践中最常见的恶性肿瘤之一,目前正在使用这项新技术进行研究。这篇综述的重点是描述MRgRT治疗PC的现状和临床结果。简要介绍了现有的技术,以及已发表的文献和可能的未来应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
202
审稿时长
2 months
期刊介绍: Technology in Cancer Research & Treatment (TCRT) is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.
期刊最新文献
Retraction: Bifidobacteria Expressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice. ACOSA: A Script-Based Algorithm for Multi-Disease Target Crop and Optimization in Radiotherapy. Historic Real-World Outcomes and Future Benchmarks for Patients with Diffuse Large B-Cell Lymphoma Receiving First- and Second-Line Therapy in Austria - a Large Single-Center Experience. Evaluation of Anti-BNLF2b Antibody and Epstein-Barr Virus Biomarkers for the Diagnosis of Nasopharyngeal Carcinoma: A Retrospective Study. CCT3 Facilitates the Malignant Progression of NSCLC and SCLC via PI3 K/AKT-EMT Axis and Emerges as a Novel Serum Diagnostic Biomarker.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1